{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li D"],"funding":["the Education Reform Project of Chongqing Municipal Education Commission","the Research Incubation Project of the Third Affiliated Hospital of Chongqing Medical University"],"pagination":["20420986241274909"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11380128"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15"],"pubmed_abstract":["<h4>Background</h4>The use of antineoplastic agents is one of the important triggers of tumor lysis syndrome (TLS), but there is still a lack of comprehensive understanding of antineoplastic agents that may trigger TLS and the TLS risk differences between different antineoplastic agents.<h4>Objectives</h4>This study aims to investigate the TLS risk of different antineoplastic agents and provide reference information for clinical practice.<h4>Design</h4>Real-world adverse events data in the FDA Adverse Event Reporting System (FAERS) database were used as the basis for the disproportionality analysis.<h4>Methods</h4>We reviewed the TLS reports in the FAERS database from 2004 to 2022 to summarize an antineoplastic agent list that was reported to trigger TLS, based on which we conducted dispro"],"journal":["Therapeutic advances in drug safety"],"pubmed_title":["Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database."],"pmcid":["PMC11380128"],"funding_grant_id":["234035","KY22038"],"pubmed_authors":["Du Q","Li D","Du D","Wang H","Liu S","Wang Y","Qin C"],"additional_accession":[]},"is_claimable":false,"name":"Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.","description":"<h4>Background</h4>The use of antineoplastic agents is one of the important triggers of tumor lysis syndrome (TLS), but there is still a lack of comprehensive understanding of antineoplastic agents that may trigger TLS and the TLS risk differences between different antineoplastic agents.<h4>Objectives</h4>This study aims to investigate the TLS risk of different antineoplastic agents and provide reference information for clinical practice.<h4>Design</h4>Real-world adverse events data in the FDA Adverse Event Reporting System (FAERS) database were used as the basis for the disproportionality analysis.<h4>Methods</h4>We reviewed the TLS reports in the FAERS database from 2004 to 2022 to summarize an antineoplastic agent list that was reported to trigger TLS, based on which we conducted dispro","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-05-29T11:55:04.57Z","creation":"2025-04-05T13:57:12.596Z"},"accession":"S-EPMC11380128","cross_references":{"pubmed":["39247253"],"doi":["10.1177/20420986241274909"]}}